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78Background: The National Institute for Health and Care Excellence
has recently proposed that company submissions with a base-case
incremental cost-effectiveness ratio (ICER) of less than £10,000/quality-
adjusted life-year (QALY) might be eligible for a “fast-track” appraisal.
Objectives: To explore outcomes relating to previously conducted
single-technology appraisals (STAs) with base-case ICERs of less than
£10,000/QALY.Methods: All STAs with published guidance from 2009 to
2016 were included; those with company base-case ICERs of less than
£10,000/QALY were identiﬁed and analyzed. A secondary analysis was
also conducted for those with a company base-case ICER of £10,000 to
£15,000/QALY. Relevant data were extracted and presented in a narra-
tive and in tables. Results: In total, 15% (26 of 171) of STAs included a
company submission with a base-case ICER of less than £10,000/QALY.
Of these, 73% (19 of 26) were given positive recommendations after the
ﬁrst Appraisal Committee (AC) meeting, whereas 27% (7 of 26) were
initially given a Minded Noee front matter Copyright & 2017, International S
r Inc.
.1016/j.jval.2017.09.006
ondence to: Christopher Carroll, Health Economic
eld, Regent Court, Regent Street, Shefﬁeld S1 4DA
shef.ac.uk..before receiving a positive recommendation in the ﬁnal appraisal
determination, albeit with restricted recommendations for three
technologies. Five STAs had company base-case ICERs of £10,000
to £15,000/QALY and all received a positive recommendation
after the ﬁrst AC meeting. Conclusions: Most previous STAs with
a company base-case ICER of £10,000 or even £15,000/QALY received a
positive recommendation after the ﬁrst AC meeting, but a number of
them proved more complicated and required detailed appraisal,
which inﬂuenced the ﬁnal recommendation. This ﬁnding might have
implications for the proposed fast-track process of the National
Institute for Health and Care Excellence.
Keywords: base-case ICERs, health policy, National Institute for Health
and Care Excellence (NICE), single-technology appraisals (STAs).
Copyright & 2017, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98Introduction
The National Institute for Health and Care Excellence (NICE)
single-technology appraisal (STA) process has been in existence
since 2005. The process is undertaken for a technology for a
single indication; it is outlined in detail in the Guide to the Single
Technology Appraisal Process [1] and includes the production of a
submission by the company that manufactures the technology.
The company’s submission (CS) to NICE forms the principal
source of evidence for decision making in the STA process. The
CS is expected to contain an evaluation of the clinical effective-
ness and cost-effectiveness of the technology using decision-
analytic approaches outlined in the NICE Guide to the Methods of
Technology Appraisal [2]. The CS should also include an incre-
mental cost-effectiveness ratio (ICER), expressed as cost per
quality-adjusted life-year (QALY), as the measure of the technol-
ogy’s cost-effectiveness. An independent, academic evidencereview group (ERG) is charged with the task of critically apprais-
ing the CS to identify strengths, weaknesses, and gaps in the
evidence presented. The ERG also undertakes exploratory analy-
ses to explore uncertainties around the company’s model and
resulting ICERs [3,4]. The ERG report, together with the CS, is
considered by one of the four NICE Technology Appraisal Com-
mittees (ACs) in their deliberations. The ﬁndings of the commit-
tee are used to produce the appraisal consultation document
(ACD); after further considerations and a consultation period, a
ﬁnal appraisal determination (FAD) is produced that results in
NICE guidance. In some cases, only a FAD is produced, without
the need for an ACD. Within these documents are listed a
company’s submitted base-case ICER (or range), the ERG’s pre-
ferred ICER (or range), the AC’s preferred ICERs, as well as the
committee’s recommendations. On the whole, technologies are
recommended for reimbursement if their ICER does not exceed
the generally accepted NICE threshold of £20,000 to £30,000/QALY99
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V A L U E I N H E A L T H ] ( 2 0 1 7 ) ] ] ] – ] ] ]2[2,5], although there is evidence that this threshold might some-
times be higher, even for technologies that do not satisfy criteria
for end-of-life or being “highly specialized” [6,7].
Changes to the NICE STA process have recently been proposed
after consultation [8]. One of the proposals, and the focus of this
article, is that a new “fast-track” appraisal (FTA) process, a variant
of the standard appraisal process, might be applied when a
company submits a base-case ICER of less than £10,000/QALY
[8]. According to the consultation document, the stated intention
behind the proposal appears to be twofold: 1) to reduce the time
from a technology’s approval by the European Medicines Agency
to its being made available in the National Health Service in
England and Wales and 2) to reduce resource use by the
companies and NICE by conducting an abbreviated technology
appraisal process (shorter, less extensive evidence review proc-
esses by ERGs and fewer AC meetings) [8]. It is worth noting that
a second NICE consultation took place, which also proposed an
“accelerated technology appraisal” process. This particular proc-
ess was intended to fast-track treatments that were “likely to
provide similar or greater health beneﬁts at a similar or lower
cost than technologies already recommended in technology
appraisal guidance for the same indication” [9]. After the con-
sultation this was integrated into the FTA process, but it is not
the subject of this article.
This project was designed to explore how many STAs (2009–
2016) had an original company base-case ICER of less than
£10,000/QALY and how many, after the full appraisal process,
were recommended in the ﬁrst ACD and in the FAD. It also
assessed whether and by how much the ICER(s) preferred by the
AC and stated in the ACD and in the FAD were different from the
original company base-case ICER(s), especially if the ICER
exceeded the generally accepted NICE threshold of £20,000 to
£30,000/QALY [2,5]. This enabled an evidence-based assessment
of the outcomes for previous STAs with company base-case ICERs
of less than £10,000/QALY.
The research therefore aimed to answer the following
questions:
1. How many STAs had a company submitted base-case ICER of
less than £10,000/QALY, or the technology dominated its
principal comparator?
2. How many of these technologies received a positive recom-
mendation in the ACD (or in the FAD, in those cases without
an ACD)?
3. How many of these technologies received a “No” or “Minded
No” in the ACD?
4. What reasons were given in the ACD for not recommending
the technology?
5. What was the ﬁnal ICER and recommendation in the FAD?
A secondary analysis was also conducted on STAs with an
original company base-case ICER of between £10,000 and £15,000/
QALY to determine whether outcomes were any different for this
group.F1
T1
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A content analysis was undertaken of documents relating to all
STAs conducted by NICE between 2009 and December 2016 by
members of research teams from the University of Shefﬁeld and
the University of Liverpool. This study focuses on 2009 onward
because the STA process, after 4 years of development, had become
largely standardized by this point [10]. A ﬁrst screen was conducted
to identify those STAs with a company base-case ICER of less than
£10,000/QALY, as reported in the ﬁrst ACD (or FAD if there was no
ACD). More extensive data were then extracted into a standard formfrom the ACD and FAD documents relating to these STAs. The data
to be extracted included the following: technology appraisal (TA)
number, title of STA, date of FAD, name of company, ERG, disease
area, company base-case ICERs, AC-preferred ICERs in the ACD, ACD
recommendation (and details), AC-preferred ICERs in the FAD, and
the FAD recommendation (and details).
Data from the ﬁrst 100 STAs with FADs had been collected for
a previous project, which covered STAs from March 2009 to
March 2014 [3,4,6]. These data were extracted and checked by
the two reviewers from the Shefﬁeld team and, in some instan-
ces, checked also by a member of the Liverpool team. When
necessary, the original documents were all rechecked. The
relevant documents of STAs from April 1, 2014, to December
2016 were publicly available on the NICE Web site and were
checked and extracted by one member of the Liverpool team and
double-checked by a second member. All ambiguous data were
checked and discussed with all other members of the project
team. The principal ﬁndings are summarized in a narrative and
presented in tables, when relevant. Any instances in which a
technology was not recommended wholly in line with the
original submission are discussed in detail, as are the issues that
became apparent when examining these data.Results
Between September 2009 and December 2016, there were 171
STAs for which ﬁnal guidance had been published. These did not
include STAs that had been withdrawn or for which the process
had started but had been suspended. Nor did it include STAs in
which the relevant ICERs were commercial-in-conﬁdence (e.g.,
TA410), in which all the necessary documents are not available
online (e.g., TA368, TA372, TA376, and TA396) or in which no
company base-case ICER was reported (a cost-minimization
analysis) (e.g., TA191). Such STAs were therefore excluded from
this analysis because the ICERs were absent or unusable. The
ﬁnal total was 171 STAs, for which ﬁnal guidance had been
published. Out of these 171 STAs, 117 were excluded because
none of the company base-case ICERs reported in the ACD or FAD
was £10,000/QALY or less (or dominated the principal compara-
tors). Nevertheless, ﬁve of these STAs had company base-case
ICERs between £10,000 and £15,000/QALY (TA216, TA275, TA345,
TA355, and TA400). These were considered a potential group of
interest, and so are considered separately later. Out of the
remaining 54 STAs, 28 had multiple company base-case ICERs
for the principal indication (because of the provision of ICERs for
different scenarios, comparisons, and subgroups), one or more of
which was less than £10,000/QALY and one or more of which was
more than £10,000/QALY. These were excluded from the primary
analysis because they were unlikely to be fast-tracked given the
presence of ICERs of more than £10,000/QALY for certain relevant
subgroups or comparisons. These STAs are also considered in
more detail later. The total number of STAs with company base-
case ICERs that all either dominated current treatments or were
less than £10,000/QALY in all comparisons was 26, which repre-
sents 15% (26 of 171) of all STAs with usable ICERs and published
guidance. This is consistent with the 15% ﬁgure quoted by NICE
[8]. A ﬂowchart of the selection process is shown in Figure 1.
STAs with All Company Base-Case ICERs of Less Than
£10,000/QALY or Dominating Comparators
The technologies in 19 of these 26 STAs (73%) received a positive
recommendation after the ﬁrst AC meeting. In 13 of these 19
STAs (68%) only a FAD was issued; there was no ACD (see
Table 1). In 8 of these 13 STAs (62%), the companies’ base-case
ICERs (or conclusion on dominance), as recorded in the
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STAs
n=171
No or Minded No in first 
ACD before eventual 
positive recommendation
n=7
STAs
n=54
Positive recommendation 
in first ACD or FAD
n=19
117 STAs with company 
base-case ICERs all 
>£10K per QALY 
(5/117 STAs with 
company base-case ICERs 
all >£10K and <£15K per 
QALY†)
STAs with company base-
case ICERs all <£10K* per 
QALY
n=26
28 STAs with one or more 
company base-case ICERs 
<£10K* but also one or 
more other company base-
case ICERs of >£10K per 
QALY
†£10-15K=TA216, 275, 345, 355, 400                          *Or that dominate comparator(s)
Fig. 1 – PRISMA ﬂowchart of STA selection process. ACD, appraisal consultation document; FAD, ﬁnal appraisal determination;
ICER, incremental cost-effectiveness ratio; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses;
QALY, quality-adjusted life-year; STA, single-technology appraisal.
V A L U E I N H E A L T H ] ( 2 0 1 7 ) ] ] ] – ] ] ] 3committee documents, remained the preferred ICER of the
committee (including technologies with a patient access
scheme [PAS] in the case of TA305). In the other ﬁve STAs, the
AC-preferred ICER in the FAD was not explicitly stated (because of
a PAS in the case of TA294) in three cases and was higher in two
cases, but each technology was stated to be cost-effective. For 6 of
the 19 technologies that generated positive recommendations,
ﬁrst in an ACD and then later in the FAD, the AC-preferred ICER
in the FAD was the same as the company’s base-case ICER in one
STA and higher than the company’s base-case ICER in ﬁve STAs
(but still o£10,000/QALY in four STAs). In one STA (TA335), the
AC-preferred ICER in the FAD, and its relationship to the com-
pany base-case ICER, was unclear. The details of these 19 STAs
are presented in Table 1.
Seven of the 26 STAs with all company base-case ICERs of less
than £10,000/QALY received a Minded No in the ﬁrst ACD. All
these technologies ultimately received a positiverecommendation in the FAD, but in some cases this recommen-
dation was restricted by subgroup. The details of these seven
STAs are presented in Table 2. In each case, the AC considered
that the analyses provided by both the company and the ERG
were inadequate for making a decision, and the AC could not
identify a plausible ICER per QALY on the basis of the evidence
and model as presented.
Four of the seven technologies were recommended fully in the
FAD. Nevertheless, it should be noted that despite all four of
these technologies originally dominating comparators or having
company ICERs of less than £10,000/QALY, almost all the ﬁnal
ICERs preferred by the AC and stated in the FADs fell between
£10,000 and £30,000/QALY, on the basis of the additional analyses
requested by the AC and conducted by the company or ERG.
The remaining three of these seven STAs had more restrictive
recommendations in the FAD. Two involved treatments for
mental health conditions: aripiprazole for adolescent374
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Table 1 – Summary of STAs with company base-case ICERs o£10,000/QALY that received a positive recommendation at ﬁrst time of asking.
TA number FAD date Technology Disease area ERG ACD, FAD FAD-preferred ICER Relative to
original ICER
230 2011 Bivalirudin Cardiovascular ScHARR FAD Dominates Same*
236 2011 Ticagrelor Cardiovascular LRiG ACD, FAD o£10,000 Higher
264 2012 Alteplase Cardiovascular ScHARR FAD o£10,000 Same†
267 2012 Ivabradine Cardiovascular BMJ Evidence ACD, FAD o£10,000 Same
290 2013 Mirabegron Urogenital BMJ Evidence ACD, FAD o£10,000 Higher
292 2013 Aripiprazole Mental health ScHARR FAD Dominates Unclear
294 2013 Aﬂibercept Eye Aberdeen FAD Dominates (with PAS) Same†
298 2013 Ranibizumab Eye Aberdeen FAD Dominates Same
305 2014 Aﬂibercept Eye Warwick FAD o£10,000 and dominates (with PAS) Same
318 2014 Lubiprostone Digestive system York CRD FAD Dominates Same
325 2014 Nalmefene Alcohol dependence ScHARR ACD, FAD o£10,000 Higher
327 2014 Dabigatran etexilate Cardiovascular BMJ FAD Unclear but within acceptable range Higher
335 2015 Rivaroxaban Cardiovascular ScHARR ACD, FAD Unclear but within acceptable range Unclear
346 2015 Aﬂibercept Eye Aberdeen ACD, FAD Unclear but within acceptable range (with PAS)‡ Higher
350 2015 Secukinumab Psoriasis Aberdeen FAD Unclear but within acceptable range (with PAS) Unclear
366 2015 Pembrolizumab Cancer LRiG FAD Unclear but within acceptable range (with PAS)‡ Unclear
407 2016 Secukinumab Musculoskeletal Kleijnen SR FAD o£10,000 (with PAS) Same
408 2016 Pegaspargase Blood and immune Kleijnen SR FAD Dominates Same
418 2016 Dapagliﬂozin Diabetes Warwick FAD Unclear but within acceptable range Higher
ACD, appraisal consultation document; CRD; ERGQ5 , evidence review group; FAD, ﬁnal appraisal determination; ICER, incremental cost-effectiveness ratio; LRiG; PAS, patient access scheme; QALY,
quality-adjusted life-year; ScHARR, School of Health and Related Research; STA, single-technology appraisal; TA, technology appraisal.
* Different ﬁgures, but still dominates.
† A speciﬁc ﬁnal ICER was conﬁdential or not reported.
‡ Includes PAS for comparators.
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Table 2 – Summary of STAs with company base-case ICERs o£10,000/QALY that received an initial Minded No recommendation in the ACD.
TA
number
FAD
date
Technology Disease area ERG ACD reason for decision FAD decision FAD ICER (source)
213 2011 Aripiprazole Mental health Southampton 4.7, 4.12: The AC requested more
evidence on comparisons other
than olanzapine, especially for
risperidone, the principal,
routinely used comparator in UK
clinical practice.
1.1: Recommended only in a
subgroup of the original
indication (people aged 15–17 y
who are intolerant of
risperidone, or for whom
risperidone is contraindicated,
or whose schizophrenia has not
been adequately controlled with
risperidone)
4.12: As ﬁrst line, the ICERs ranged
from £52,750 to £108,800 when
compared with treatment
sequences in which risperidone
is used ﬁrst (company’s updated
base-case analysis)
4.14: The AC was concerned that,
because of a number of
uncertainties in the model, the
ICER could be as high as
£233,000/QALY gained (in line
with sensitivity analyses
conducted by the ERG) and that
aripiprazole was dominated by
risperidone in the ERG’s
exploratory analyses.
229 2011 Dexamethasone
implants
Eye Aberdeen 4.35: Submission did not compare
the new technology with any of
the active comparators listed in
the scope and identiﬁed by the
ERG along with other
stakeholders. Cost of treatment
and extrapolations beyond data
from the trial “were not plausible
and did not reﬂect clinical
practice in the UK.” The
committee was therefore unable
to estimate the most plausible
ICER.
1.1: Recommended 4.20: £26,300 (company’s updated
base-case analysis)
260 2012 Botulinum toxin
type A
Chronic
migraine
Warwick 4.19: On the basis of the evidence
submitted to the AC, it was
unable to conclude whether
botulinum toxin type A was cost-
effective compared with
standard care. The central
estimate of probabilistic ICER
was not presented and there was
uncertainty in many of the
modeled parameters.
1.1: Recommended 4.15: £18,900 (ERG analysis of
company’s updated base-case
analysis)
261 2012 Rivaroxaban Blood and
immune
ScHARR 1.2, 4.13, 4.15, 4.16: The main
limitation of the model from the
AC’s point of view was that
patients were treated with the
drug only for 12 mo, yet in
practice people may need
ongoing anticoagulation. The AC
also considered the assessment
of cost-effectiveness in different
subgroups to be uncertain and
therefore requested further
evidence to support the
assumptions.
1.1: Recommended 4.13, 4.16: Most likely ICERs based
on length of treatment duration
ranged from dominating
comparators (3 mo) to £19,400/
QALY for people who need
treatment beyond 12 mo (ERG
analysis)
continued on next page
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Table 2 – continued
TA
number
FAD
date
Technology Disease area ERG ACD reason for decision FAD decision FAD ICER (source)
308 2014 Rituximab Blood and
immune
ScHARR 4.17: The AC concluded that none of
the ICERs presented by the
manufacturer and the ERG
provided an accurate cost-
effectiveness estimate because of
uncertainties pertaining to
model parameters, such as
unrealistic outpatient costs and
utility values and incomplete and
inappropriate treatment
sequences. Additional analyses
were needed.
1.1: Recommended only if further
cyclophosphamide treatment
would exceed the maximum
cumulative cyclophosphamide
dose; or cyclophosphamide is
contraindicated or not tolerated;
or the person has not completed
their family, and treatment with
cyclophosphamide may
materially affect their fertility;
or the disease has remained
active or progressed despite a
course of cyclophosphamide
lasting 3–6 mo; or the person
has had uroepithelial
malignancy
4.18: £12,100 for people who can
have cyclophosphamide; o
£30,000 for those who cannot
(ERG analysis)
312 2014 Alemtuzumab Central
nervous
system
Southampton 4.10, 4.11: The AC concluded that
the primary outcome measure
for the MTC should be sustained
accumulation of disability lasting
6 mo because this was a
coprimary outcome in the
clinical trials.
1.1: Recommended 4.21: ICER considered to be
between £13,600 and £24,500
compared with glatiramer
acetate and £8,900 (4.22)
compared with ﬁngolimod for a
different population (company’s
updated base-case analysis)
The number of QALYs accumulated
over the lifetime of the model
was deemed to be implausibly
low.
367 2015 Vortioxetine Mental health York CRD 1.2, 4.12, 4.20: The only population
modeled was for second-line
treatment; AC was interested in
other comparisons/lines.
1.1: Recommended only in those
people who have had an
inadequate response to two
antidepressants within the
current episode (third line)
4.12: All scenario ICERs against all
comparators were o£9,000
when equal efﬁcacy between
treatments is assumed
(company’s updated base-case
analysis)
4.12, 4.13, 4.16: The AC thought that
the model structure lacked
validity and that the resource use
and costs did not reﬂect the
pathway of care for the indicated
population.
AC, Appraisal Committee; ACD, appraisal consultation document; CRD; ERGQ6 , evidence review group; FAD, ﬁnal appraisal determination; ICER, incremental cost-effectiveness ratio; MTC, mixed
treatment comparison; PAS, patient access scheme; QALY, quality-adjusted life-year; ScHARR, School of Health and Related Research; STA, single-technology appraisal; TA, technology appraisal.
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V A L U E I N H E A L T H ] ( 2 0 1 7 ) ] ] ] – ] ] ] 7schizophrenia (TA213) and vortioxetine for major depressive
episodes (TA367). In TA213, aripiprazole was originally indicated
in the CS as a ﬁrst-line therapy for the treatment of schizophre-
nia in adolescents (aged 15–17 years) and the company base-case
ICER was reported as £6200/QALY compared with olanzapine.
Nevertheless, the AC considered the principal comparator to be
risperidone; ERG analyses had reported much higher ICERs for
this comparison. Given that the ﬁnal ICERs for aripiprazole as a
ﬁrst-line therapy were in excess of £30,000/QALY, the ﬁnal
recommendation restricted its use to ﬁrst-line therapy only for
patients who were intolerant to, or contraindicated for, the
principal treatment, risperidone. In a similar way, the CS in
TA367 had restricted vortioxetine to second-line treatment, but
the FAD recommendation restricted reimbursement to third-line
treatment, that is, for patients who had had an inadequate
response to two antidepressants within the current episode.
Once more, the initial Minded No recommendation was due in
part to the AC stating that relevant comparisons were absent
from the CS. The third STA with restricted recommendations was
for rituximab for antineutrophil cytoplasmic antibody–associated
vasculitis (TA308). The initial Minded No was because the AC was
uncomfortable with uncertainties in the models submitted by the
company and supplemented by the ERG and therefore requested
further analyses. As a result of these analyses, and contrary to
the CS, the FAD recommended only rituximab for treatment-
naive patients in certain circumstances.
Overall, the principal reasons for the Minded No recommen-
dations in these seven STAs, despite their low ICERs, might be
summarized as follows (a single submission might be affected by
a number of issues): implausible results or ICERs due to the
models’ failure to reﬂect clinical practice (TA229, TA261, and
TA367) or uncertainties in the model parameters or assumptions
(TA213, TA260, TA261, TA308, and TA367). The need for addi-
tional analyses was also precipitated by a failure of the models to
take into account or use the comparisons (TA213, TA229, and
TA367) or outcomes (TA312) that the ACs deemed most relevant.880
881
882
883
884
885
886
887
888
889
890
891
892STAs with Company Base-Case ICERs of £10,000 to £15,000/
QALY
Given that the proposed ﬁgure of £10,000/QALY for NICE fast-
track consideration is not an absolute, we present here the
evidence from ﬁve further STAs from our sample in which all
the company base-case ICERs were less than £15,000/QALY. That
is, if one of the criteria for FTA was to be set at £15,000/QALY,
then an additional ﬁve STAs become relevant to our analysis;
thus, in total, 31 of 171(18%) previously completed STAs would be
potentially eligible. These ﬁve additional STAs are presented in
Table 3.Table 3 – Summary of STAs with company base-case ICE
TA
number
FAD
date
Technology Disease area
216 2011 Bendamustine Cancer P
275 2013 Apixaban Cardiovascular BM
345 2015 Naloxegol Digestive
system
Kle
355 2015 Edoxaban Cardiovascular
400 2016 Nivolumab Cancer BM
ACD, appraisal consultation document; ERG, evidence review group; FAD
ratio; LRiG; PAS, patient access scheme; QALY, quality-adjusted life-year
⁎ As long as combination technology is costed according to its PAS.As with most of the STAs with all company base-case ICERs of
less than £10,000/QALY that did not receive a Minded No in the
ACD, all ﬁve of these STAs received a positive recommendation in
the ﬁrst AC meeting (only a FAD was produced, and there was no
ACD). In three cases, the AC-preferred ICER in the FAD (the result
of ERG analyses in each case) was higher than the original
company base-case ICER, but all were less than a cost-effective-
ness threshold of £30,000/QALY. Unlike the STAs considered in
Table 1, this group includes two cancer technologies: bendamus-
tine for chronic lymphocytic leukemia (TA216) and nivolumab for
advanced melanoma (TA400).
STAs with Company Base-Case ICERs Ranging from Less
Than £10,000/QALY to More Than £10,000/QALY
In total, 28 of 171 (16%) relevant STAs in this sample had one or
more company base-case ICERs of less than £10,000/QALY as well
as one or more ICERs of more than £10,000/QALY (see Table 4).
These were evenly spread across disease areas and ERGs, but it is
noticeable that the last 2 years had more such STAs than the
previous 6 years (15 for 2015–2016 compared with 13 for 2009–
2014). This perhaps reﬂects the increasing complexity of the
assessments being conducted in the NICE STA process.
It is no surprise that the picture for these 28 STAs is far more
fragmentary than for those 26 STAs with all the company base-
ICERs less than £10,000/QALY. Only 39% (13 of 28) received an
unrestricted, positive recommendation at the ﬁrst AC. In seven of
these, no ACD was produced at all (only a FAD was produced),
that is, 25% (7 of 28) compared with 50% (13 of 26) in the group
with company base-ICERs all less than £15,000/QALY. Further-
more, technologies received a No or Minded No for all groups in
25% (7 of 28) of these STAs after the ﬁrst AC and others were
recommended in speciﬁc subgroups or circumstances only in 29%
(8 of 28). All the technologies in these 28 STAs ultimately received
a positive recommendation in the FAD, but in 32% (9 of 28) the
recommendation was restricted to certain subgroups or lines of
treatment and, in seven cases, it was conditional on a PAS. In ﬁve
of these seven cases, the PAS had been submitted along with the
original CS (see Table 4).Discussion
Twenty-six STAs in this sample would have satisﬁed the basic
criterion for the proposed NICE FTA process; that is, all of a
company’s submitted base-case ICERs for a technology and
indication were less than £10,000/QALY. Following the example
of previous STAs, this approach would make up to 18% of future
STAs eligible for such an FTA process. Our analysis found that
73% (19 of 26) of these STAs received a straightforward, positive893
894
895
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902
903
904
905
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909
910
Rs of £10,000–£15,000/QALY.
ERG ACD, FAD FAD-preferred
ICER
Relative to
original ICER
ENTAG FAD o£10,000 Lower (£12,000)
J Evidence FAD o£20,000 Higher
ijnen SR FAD o£13,000 Same
LRiG FAD o£16,000 Higher
J Evidence FAD o£30,000*
(with PAS)
Higher
, ﬁnal appraisal determination; ICER, incremental cost-effectiveness
; STA, single-technology appraisal; TA, technology appraisal.
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Table 4 – Summary of STAs with company base-case ICERs ranging from less than to more than £10,000/QALY.
TA number FAD date Technology Disease area ERG ACD decision FAD decision
182 2009 Prasugrel Cardiovascular LRiG Recommended Recommended
186 2010 Certolizumab pegol Musculoskeletal West Midlands Minded No Recommended (with PAS*)
197 2010 Dronedarone Cardiovascular York CRD Not recommended Recommended for second-line treatment only
203 2010 Liraglutide Blood and immune Aberdeen Restricted recommendations Recommended (in certain subgroups)
248 2012 Exenatide Blood and immune Warwick Recommended Recommended
249 2012 Dabigatran etexilate Cardiovascular York CRD Minded No Recommended
252 2012 Telaprevir Hepatitis Southampton No ACD Recommended
253 2012 Boceprevir Hepatitis Southampton No ACD Recommended
287 2013 Rivaroxaban Blood and immune Southampton No ACD Recommended
293 2013 Eltrombopag Blood and immune Aberdeen Recommended Recommended
315 2014 Canagliﬂozin Endocrine Southampton Restricted recommendations Recommended (in certain subgroups)
317 2014 Prasugrel Cardiovascular LRiG Recommended Recommended
326 2014 Imatinib Cancer Southampton Recommended Recommended
330 2015 Sofosbuvir Hepatitis Southampton Minded No Recommended
331 2015 Simeprevir Hepatitis Southampton Restricted recommendations Recommended
336 2015 Empagliﬂozin Endocrine Warwick Minded No Recommended (in certain subgroups)
341 2015 Apixaban Cardiovascular LRiG No ACD Recommended
342 2015 Vedolizumab Digestive system ScHARR Restricted recommendations Recommended (with PAS*)
349 2015 Dexamethasone implants† Eyes BMJ Evidence Restricted recommendations Recommended (in certain subgroups)
354 2015 Edoxaban Cardiovascular BMJ Evidence No ACD Recommended
359 2015 Idelalisib Cancer Warwick Minded No and No Recommended (in certain subgroups) (with PAS*)
363 2015 Ledipasvir/sofosbuvir Hepatitis ScHARR Restricted recommendations Recommended (in certain subgroups) (with PAS)
364 2015 Daclatasvir Hepatitis York CRD Restricted recommendations Recommended (in certain subgroups) (with PAS)
365 2015 Ombitasvir/paritaprevir/
ritonavir ± dasabuvir
Hepatitis Southampton Recommended Recommended
384 2016 Nivolumab† Cancer Southampton No ACD Recommended
413 2016 Elbasvir-grazoprevir Hepatitis Kleijnen SR No ACD Recommended (with PAS*)
415 2016 Certolizumab pegol Musculoskeletal ScHARR Restricted recommendations Recommended (in certain subgroups) (with PAS*)
424 2016 Pertuzumab Cancer ScHARR Not recommended Recommended
ACD, appraisal consultation document; CRD; ERG, evidence review group; FAD, ﬁnal appraisal determination; ICER, incremental cost-effectiveness ratio; LRiGQ8 ; PAS, patient access scheme; QALY,
quality-adjusted life-year; ScHARR, School of Health and Related Research; STA, single-technology appraisal; TA, technology appraisal.
⁎ PAS submitted with original company submission.
† Includes PAS for comparators.
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V A L U E I N H E A L T H ] ( 2 0 1 7 ) ] ] ] – ] ] ] 9recommendation with an AC-preferred ICER in the FAD that fell
below the £30,000/QALY threshold of cost-effectiveness generally
applied by NICE [2,5].
Nevertheless, the seven STAs with company base-case ICERs
of less than £10,000/QALY that received a Minded No in the ACD
give particular pause for thought when considering the implica-
tions of these ﬁndings for the proposed FTA process. In four of
these STAs, the AC-preferred ICERs in the FAD, as a result of
additional analyses performed by the company or the ERGs, had
risen to almost £30,000/QALY (still within existing thresholds of
cost-effectiveness). Yet in the other three STAs (TA213, TA308,
and TA367) the result was a recommendation restricted to certain
subgroups or lines of treatment. In the case of TA213, the ﬁnal
preferred ICERs for the original proposal of ﬁrst-line treatment
were well in excess of the £30,000/QALY threshold. The National
Health Service could therefore have ended up paying for a
treatment for certain patients that might normally have been
designated as “not cost-effective,” with the obvious implications
and opportunity costs [5,11,12]. It might be the case that the
health system would be willing to fund non–cost-effective treat-
ments for certain subgroups in return for providing more timely
access to new treatments and a faster, less expensive TA process
[8], although some might disagree [12].
The NICE proposal has stated that criteria for inclusion in the
FTA process would be “the availability of strong evidence (with a
low degree of decision uncertainty)” and that the ICER is indeed
likely to be less than £10,000/QALY. It was also anticipated that
such technologies would be identiﬁed by NICE “following an
analysis of the company’s submission, supported by external
review” [8]. It is possible that STAs with issues, such as the seven
STAs with a company base-case ICER of less than £10,000/QALY,
and which received a Minded No in the ACD, might have been
identiﬁed by this process and “re-routed” to the standard STA
process. After all, the CS and models in four of these seven STAs
were potentially easily identiﬁable as having a high degree of
decision uncertainty on account of their failure to provide
comparisons against the most relevant current treatments
(TA213, TA229, and TA367) and/or their failure to reﬂect UK
clinical practice (TA229, TA261, and TA367). It is, however,
questionable whether a more limited appraisal process might
have identiﬁed the uncertainties in the model parameters
and assumptions that affected ﬁve of these STAs (TA213,
TA260, TA261, TA308, and TA367). Indeed, the current process’s
heavy reliance on the ERGs to identify such issues is well
known [3].
On the basis of the evidence, the group of 26 STAs with ICERs
less than £10,000/QALY, and the group of ﬁve STAs with ICERs
between £10,000 and £15,000/QALY, all do appear to represent a
generally quite homogeneous type of STA. Only 13 of these 31
STAs had multiple ICERs and, of course, the range was very
narrow (from the new technology dominating comparators to
always being o£15,000/QALY). This means that 18 of these 31
STAs (58%) had only a single company base-case ICER. The
groups and scenarios within these appraisals were fairly homo-
geneous and thus required a less complex methodology than did
other STAs. This accords with the NICE consultation proposal
that “the weight and complexity” of the appraisals should be “in
proportion to the technical challenges and the risks posed by the
evidence that it considers” [8]. And thus, the FTA process was
only to be for “the appraisal of health technologies for which a
conﬁdent judgement about value for money can be made at an
early stage” [8]. Nevertheless, such a judgment could not possibly
be made, for example, for the 28 STAs with company base-case
ICERs both less than and more than £10,000/QALY, in which
companies submitted multiple base-case ICERs for their technol-
ogy, which might range from dominating to being dominated by
comparators (e.g., TA349) on account of different subgroups,treatment lines, or scenarios. Such technologies must be
appraised via the standard process.
Another scenario arises when a relevant comparator product
already has a conﬁdential PAS in place with the Department of
Health. In this case, an ERG is required to generate results taking
into account all the PAS discounts. In our data set, two of the
STAs (TA346 and TA366) with company base-case ICERs of less
than £10,000/QALY were subject to this additional process, as
were two STAs (TA384 and TA415) within the group containing
multiple ICERs, some of which were less than £10,000/QALY. This
information can be identiﬁed at the outset and would allow some
technologies to be quickly categorized as not being eligible for the
FTA process, if the presence of such an issue was deemed to
require more work.
One particular pattern is noticeable in the 19 STAs with all
ICERs less than £10,000/QALY and with straightforward positive
recommendations. Six of the 19 (32%) comprise treatments for
cardiovascular disease and 4 (21%) relate to treatments for eyes.
We consider that these disease areas are disproportionately
highly represented in this group. In a study of the ﬁrst 100 STAs
with published guidance (2009–2014), frequencies were 11% for
cardiovascular disease therapies and 7% for eye therapies and
treatments for cancer; for blood and immune system and mus-
culoskeletal conditions, frequencies were all higher than 7%
[4,6,10]. In our data set, three of the four “eye” STAs evaluated
aﬂibercept for different indications and this drug has a relatively
low-intensity regimen (with relatively low associated costs)
compared with currently licensed comparators [13], for example,
ranibizumab, which was the subject of the fourth “eye” STA. The
relatively higher proportions of cardiovascular and eye treat-
ments in this sample of STAs might also be due in part to the
lower costs of treatments for these particular disease areas
relative to others, such as cancer or musculoskeletal conditions
[14,15]. There did not appear to be any particularly noticeable
increase in these STAs over time (see Tables 1 and 2): there were
the same number of STAs (n ¼ 4) with a company base-case ICER
of less than £10,000/QALY in 2011, 2012, and 2013, and only slight
increases in 2014 (n ¼ 6) and 2015 (n ¼ 5). This might, however,
change in the future.
In 74% (23 of 31) of STAs with technologies with company
base-case ICERs all less than £15,000/QALY, this represented the
ﬁrst time the technology was being assessed by NICE (for any
indication). These cases therefore all potentially represented cost
precedents for future submissions, even for different indications.
In ﬁve of the remaining eight STAs (TA264, TA275, TA292, TA327,
and TA335), the technologies had received previous recommen-
dations for essentially the same indication, either as long as
5 years before the relevant appraisal, for example, alteplase for
acute ischemic stroke in 2007 (TA122) and 2012 (TA264), or as
little as 1 year before the relevant appraisal, for example,
apixaban for embolisms in 2012 (TA245) and 2013 (TA275). In
only three cases were there previous appraisals of the same
technology for different indications: bendamustine for treating
chronic lymphocytic leukemia in 2011 (TA216) had been preceded
by bendamustine for non-Hodgkin lymphoma in 2010 (TA206);
rituximab for treating antineutrophil cytoplasmic antibody–asso-
ciated vasculitis in 2014 (TA308) had been preceded by TAs for a
number of lymphoma indications and rheumatoid arthritis
between 2002 (TA37) and 2009 (TA174); and ﬁnally ranibizumab
for treating choroidal neovascularization associated with patho-
logical myopia in 2013 (TA298) had been the subject of previous
appraisals between 2008 and 2011 for macular degeneration and
macular edema (TA155, TA229, and TA237).
The strength of this research is that it represents an analysis
of all NICE STAs with published ﬁnal guidance from September
2009 to December 2016, and thus offers an excellent summary of
current and recent practice. The double-checking of all key data
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V A L U E I N H E A L T H ] ( 2 0 1 7 ) ] ] ] – ] ] ]10across the 171 included STAs, by at least two experienced health
technology assessment researchers from two research teams
(Shefﬁeld and Liverpool), reduced the likelihood of inconsistency
and inaccuracy in the data. In addition, the method of analysis
was descriptive, which reduces the likelihood of overstating
relationships in the data, and an inclusive approach was taken
to managing data that were not straightforward, for example, the
presence of multiple ICERs.
There are, however, limitations to this study. There are
inherent weaknesses in using documentary analysis in that the
researcher is able to analyze only what has been reported. The
level and type of detail provided in and across the ACDs and FADs
could be very different, which made data extraction at times a
matter of interpretation. The so-called original company base-
case ICERs, as reported in the ACD or FAD, are possibly likely to
be different in an unknown number of instances from the ICERs
submitted by companies at the very start of the process. This is
because, as a minimum, they will have been subject to the
clariﬁcation process led by the ERG [1], and so could have already
been revised before the ﬁrst AC meeting and the committee’s
request for any revisions or additional analyses. It is also unclear
exactly how a new FTA process might be operationalized, and so
assumptions have had to be made in this study and it is not
possible to know exactly how far such a process might or might
not identify STAs with issues requiring more extensive work.
Finally, it is not possible to determine from the present study and
analysis whether the proposed FTA process will be adequate to
identify all the issues that might arise with a submission that has
a company base-case ICER of less than £10,000/QALY or how far
the existence of this criterion might inﬂuence submissions; this
study explored only what had happened with previous STAs that
satisﬁed this basic criterion. These limitations suggest that
caution should be exercised regarding some of the conclusions
drawn from the evidence.1270
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Most of the previous STAs with a company base-case ICER of £10,000
or even £15,000/QALY received a positive recommendation after the
ﬁrst AC, but a number proved more complicated and required
detailed appraisal, which inﬂuenced the ﬁnal recommendation. In
19 of the 26 STAs that satisfy the £10,000/QALY threshold in this
sample, the technologies received a positive recommendation after
the ﬁrst AC meeting with little or no amendment to the original
company base-case ICERs in the FAD. The same ﬁnding applied to
another group of ﬁve STAs with company base-case ICERs of less
than £15,000/QALY. Nevertheless, in seven of the STAs with company
base-case ICERs less than £10,000/QALY, the technology received an
initial Minded No and, in three cases (43%), the indicated patient
groups were more restricted in the ﬁnal recommendation than in the
companies’ original submissions. Additional analyses and work by
the companies and ERGs had demonstrated that the relevant base-
case ICERs might actually be much higher and the technologies
might not be cost-effective for certain patient groups. It is uncertain
whether an FTA process would have identiﬁed these issues.Source of ﬁnancial support: This project received no ﬁnancial
support.Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/j.
jval.2017.09.006 or, if a hard copy of article, at www.valueinhealth
journal.com/issues (select volume, issue, and article).
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